Background: Human immunodeficiency virus type 1 (HIV-1) is a lentivirus and shares with other members of this retroviral subfamily the ability to replicate in nondividing cells, in particular, cells of the monocyte/ macrophage lineage. This feature relies on the presence of a specific nuclear localization signal (NLS) within the viral matrix protein (MA p17), which to some degree can be complemented by the activity of the viral vpr gene product. The MA p17 NLS ensures efficient transportation of the viral preintegration complex into the nucleus of an infected macrophage and confers persistence of HIV-1 in quiescent T cells, and therefore presents an attractive target for therapeutic intervention.
(NLS) in general and the HIV-1 MA p17 NLS in particular are characterized by a stretch of positively charged amino acids including one or more lysine residues. A series of compounds potentially capable of binding and reacting with lysine by forming Schiff base adducts was synthesized. Our special consideration was to make compounds that would preferentially bind to two closely contiguous amino functions, as opposed to isolated single lysine residues. We assumed that this approach might specifically target the compound to NLS while affecting other regions less, thus reducing nonspecific cytotoxicity. Antiviral activity was assessed in primary monocytes and in peripheral blood lymphocytes (PBL) infected with HIV-ADA strain. Viral replication was monitored by reverse transcriptase (RT) activity in the supernatant. Efficiency of nuclear importation of the viral preintegration complex was estimated by the formation of 2 
INTRODUCTION
Cells of the monocyte/macrophage lineage are believed to play an extremely important role in the pathogenesis of human immunodeficiency virus (HIV) disease and may also be important in the transmission and progression of infection. Because HIV type 1 (HIV-1) strains isolated from infected individuals during the early stages of infection are predominantly monocytotropic, non-syncytium-inducing viruses (1) (2) (3) (4) , it appears that monocytes could be the earliest target of HIV infection after introduction into a new host. Low cytopathicity of the virus towards monocytes in vitro suggests that these cells might represent a productive reservoir of HIV in the body, at least early in the course of infection (5) (6) (7) (8) . Since macrophages are antigen-presenting cells that also regulate immune responses by producing a wide variety of cytokines and other bioactive molecules, HIV infection of this population could in principle account for a significant degree of dysregulation of the immune system (reviewed in Ref. 9 and 10). HIV-infected macrophages are responsible, at least in part, for such devastating and frequent complications of acquired immunodeficiency syndrome (AIDS) as central nervous system (CNS) disease (6, (11) (12) (13) and pulmonary disease (14) (15) (16) . Finally, some investigators studying HIV-1-infected chimpanzees have attributed the asymptomatic course of infection in these animals to the lack of a robust macrophage component to the infection (17) .
Recent studies have identified nuclear importation of the retroviral preintegration complex as a crucial step in HIV-1 replication in nondividing cells such as monocytes (18) . In contrast to HIV-1 replication in proliferating T ce.lls, where frank disruption of nuclear membrane during mitosis directly exposes cellular genomic DNA to viral preintegration complexes, viral propagation in nondividing monocytes relies on the active energy-dependent translocation of the preintegration complex through the intact nuclear membrane and into the nucleus (18) (19) (20) . Further work has demonstrated that nuclear importation of the HIV-1 DNA occurs in the context of the high molecular weight complex comprising viral RNA, DNA, and several viral proteins, including matrix antigen (MA p17) and virus protein R (Vpr) (21, 22) . This complex can gain access to the host genome of both proliferating and growth-arrested cells (18, (21) (22) (23) , Subsequent analysis revealed that nuclear translocation of the HIV-1 preintegration complex in growth-arrested T cells and in cultured monocytes relies on the nuclear targeting properties of the MA p17 and Vpr proteins, and in particular on the presence of a nuclear localization signal (NLS) in the N-terminal portion of MA p17 (22, 23) .
The HIV-1 MA p17 NLS belongs to a wellcharacterized class of relatively simple nuclear localization sequences. Generally, nuclear localization signals of this type are distinguished by short stretches of amino acids that contain a high percentage of basic residues. One putative consensus signal that has been proposed is Lys-Lys/ Arg-X-Lys/Arg, where X is one of a variety of amino acids (24) . The MA p17 NLS (Gly-Lys-LysLys-Tyr-Lys-Leu-Lys [23] ) conforms very well to this consensus sequence. Mutations introduced into MA p17 NLS (e.g., Gly-Thr-Thr-Lys-TyrLys-Leu-Lys) significantly attenuate viral replication in monocytes (22) and viral persistence in quiescent T cells (25) . In addition, nuclear importation of the HIV-1 preintegration complex can be partially inhibited by an excess of the prototypic NLS of simian virus 40 large T antigen (26) . These results prompted us to design a series of compounds potentially capable of binding to and reacting with the MA p17 NLS. In the present article, we describe the rationale behind the synthesis of such compounds and demonstrate their efficacy 'in blocking HIV-1 replication in primary human monocyte cultures.
MATERIALS AND MhETHODS Synthesis of Compounds
Compound H-0294 was prepared by reacting 3,5-diacetylaniline (27) with 2-amino-4-chloro-6-methylpyrimidine in water with catalytic HCI at 90-1000C for 30 min followed by base neutralization to give 2-amino-4-(3,5-diacetylphenyl)amino-6-methylpyrimidine, which was methylated by heating at reflux with a 16-fold excess of 1 in the development of infection but also a decrease in total RT activity at the peak of infection, thus indicating an irreversible inactivation of the virus by the compound. The compound was also tested on activated PBL cultures and, in accordance with our prediction, the antiviral effect was much less evident in these actively dividing cell populations (Fig. 3) . In fact, no antiviral effect was detected if cultures of replicating PBLs were infected at the multiplicity of 10 ng p24/ 106 cells. (Fig. 3A) , the same MOI as used to infect monocyte cultures, although some inhibition was observed when dividing PBL cultures were infected at a 10-fold lower MOI (Fig. 3B ).
Since we hypothesized that the activity of H1-0294 depended on its two carbonyl groups, we tested a derivative of this drug that had amidinohydrazone groups substituting both carbonyls (Compound H-2 194). In agreement with our prediction, H-2194 was significantly less active than H-0294 in monocyte cultures (Fig. 4) (22, 23) . To further substantiate this possible molecular mechanism of action, we analyzed the effect of this arylene bis(methyl ketone) compound on synthesis and nuclear importation of the viral genome following infection of monocytes. Results presented in Fig. 5 A, Phosphorimager analysis showed 2-LTR circle DNA to be 95% lower at 48 hr and 97% lower at 96 hr after infection in treated cultures (Fig. 5B) . Interestingly, similar analysis for H-2 194 demonstrated only 5-8% reduction in 2-LTR circles, corroborating the difference in potency noted for these compounds in the antiviral test (Fig. 4) . 2-LTR circle DNA represents a useful marker for successful nuclear translocation of HIV-1 DNA. This index was introduced several years ago (18) and has been shown since then to correlate well with the actual amount of viral DNA within the nuclear compartment (18, 20, 22, 23, 26) . In addition, we sought an alternative direct demonstration that the potential mechanism of antiviral action of H-0294 is its interference with nuclear translocation of the viral genome. This was accomplished by exploiting an in situ PCR technique (30) (31) (32) . Results (Fig. 6C) .
DISCUSSION
Since the discovery of HIV as the causative and pathogenic agent of AIDS, a number of potentially useful strategies for antiviral therapy have emerged (reviewed in Ref. 35 and 36). These strategies have targeted various steps of HIV replication, from binding of the virus to its cellular receptor as the initial step of infection, to the assembly of mature HIV virions and their budding from the cell membrane during the final steps. Unfortunately, relatively few drug candidates developed as a result of these endeavors have emerged as useful and efficient therapeutics in clinical practice (reviewed in Ref. 37 ). The rapid evolution of escape mutants owing to the extreme genetic lability of the virus, combined with the very nature of the retroviral life cycle, where the infectious agent integrates into the host cell genome and replicates in the same manner as normal cellular genes, have prominently mitigated against successful drug discovery efforts. Given the difficulty of interfering with expression of the virus once provirus has become established in the cellular genome, pharmaceutical approaches that target early, preintegration steps of HIV replication remain attractive strategies.
One of the early obligate steps in retroviral replication within an infected cell is the translocation of the viral genetic material into the cell nucleus (19) . This requirement was previously unappreciated as a potential target for antiretroviral therapy because most retroviruses rely on the natural disruption of the nuclear membrane during mitosis to gain access to the nuclear compartment, therefore depending on cell division for productive infection (20, 38) . HIV-1 and other members of the lentivirus subfamily of retroviruses have in addition a different mechanism to achieve nuclear access. This mechanism is employed for HIV-1 replication in nondividing cells (39, 40) and depends on the nuclear targeting properties of two viral proteins, MA p 17 and Vpr (18) (19) (20) 22, 25) . Recent studies have identified a specific nuclear localization signal (NLS) within MA p17 which is responsible for targeting the preintegration complex of HIV-1 into the nucleus of a nondividing cell (23, 25) . The HIV-1 NLS conforms closely to other well-characterized nuclear localization sequences (34) , comprising a stretch of basic amino acids, predominantly lysine residues (23) . The NLS-dependent nuclear translocation of the HIV-1 genome represents an 225 | appealing target for anti-HIV therapy because: (i) it functions prior to viral integration, such that interference with this step has the potential to prevent productive infection of the cell; (ii) it relies on a characteristic well-defined set of molecular features within the NLS that are in principal amenable to specific chemical modifications; (iii) the activity of the HIV-1 NLS is critically sensitive to base substitutions that change only one or two amino acids within the peptide (34) , suggesting that a few molecular changes within the NLS can inactivate its nuclear targeting function; and (iv) the well conserved sequence of the HIV-1 NLS suggests that escape mutants still capable of using this mechanism may evolve only infrequently.
Recognizing this potential vulnerability, a set of compounds potentially capable of binding and reacting with the free s-amino groups of lysine residues was synthesized and tested. Some of the compounds (i.e., H-0294) proved to be extremely potent inhibitors of HIV-1 replication in monocytes, with an IC50 in the low nM range. For maximal effect, these drugs had to be added to static monocyte cultures during the early stages of infection (within 24 hrs after addition of the virus to cells). This result correlates well with the kinetic of HIV-1 replication in monocytes, which shows accumulation of HIV-1 DNA within the nucleus by (22) . To achieve nuclear translocation, the HIV-1 NLS is thought to be recognized by the cellular proteins that mediate nuclear importation (43) . Chemical disruption of these cellular/viral protein/protein interactions may have been achieved by elimination of required positive charges within the NLS and/or through sterical constraints imposed by the presence of bulky drug molecules at the recognition site. Experiments designed to test directly the interaction of potential anti-NLS drugs with molecular features of the HIV-1 nuclear localization signal and to define the nature, stability, and kinetics of this interaction are now in progress. Several lines of evidence already available, however, tend to corroborate the intended direct interaction between anti-NLS compounds and MA p17 as the actual mechanism of action of anti-NLS compounds: (1) H-0294 efficiently blocks nuclear translocation of the HIV-1 genome (Fig. 5 and 6) ; (2) chemical derivatives of H-0294 lacking active carbonyl groups (e.g., H-2194), the functional groups intended to interact with the retroviral NLS, demonstrate greatly decreased antiviral activity (Fig. 4) (40, 42) . Although under some in vitro conditions, HIV-1 replication in monocytes appears to depend on cell proliferation (42, 45) , there is convincing evidence that cell division is not absolutely required for HIV-1 infection of macrophages (40) For maximal effect, anti-NLS drugs should be present at the earliest possible time after exposure of the host to infective virus. During early stages of the infection, macrophages and cells of the macrophage lineage (i.e., dendritic cells) may be the primary reservoir of HIV-1 in the body, supporting infection of T cells by antigen presentation activities (51) as well as via the release of free virus. Direct cell-to-cell transmission of the virus may constitute the major route by which infection spreads during the early stages of the disease, after resolution of the initial viremia. The molecular mechanisms of this mode of transmission are still obscure, but to the extent that nondividing cells are involved, functional NLS activity to provide access to the host cell genome will also be required and a corresponding therapeutic opportunity may therefore exist despite the absence of free virus in the blood. The realization of this possibility will depend on the design of anti-NLS compounds that are sufficiently membrane permeable to penetrate to intracellular compartments. Our preliminary experiments indicate that H-0294, for instance, can inhibit HIV-1 infection in vitro when only the viral inoculum is pre-exposed to drug and the culture remains subsequently untreated (L. Dubrovsky and M. Bukrinsky, unpublished results). Since the HIV envelope is budded from the host membrane, this suggests that anti-NLS drug candidates can be designed to diffuse through the cell membrane.
Although the potential benefits of early initiation of anti-NLS therapy seem the most promising in principle, these compounds may be helpful even if administered later in the disease. It is well established that macrophages, through the abnormal production of cytokines and other biologically active molecules, may mediate significantly the immune dysregulation observed in AIDS (reviewed in Ref. 52) . Therefore, reduction in the number of infected macrophages could potentially reduce the disruption of normal immune functions in HIV-infected individuals.
After identifying the HIV-1 nuclear localization signal on MA p17 as a potentially vulnerable retroviral target and experimentally demonstrating its critical function for viral replication in nondividing cells, we were able to design a set of candidate drugs specifically to interfere with this retroviral target. As a class, anti-NLS compounds may be useful not only against HIV, but also against other viruses that replicate in nondividing cells and therefore require nuclear transport for replication, for instance, the measles virus, which replicates in macrophages or the herpes virus that infects neurons. As the development of such anti-NLS compounds progresses, they are likely to be of particular value in combination therapy with other therapeutics that target the T cell arm of HIV-1 infection to alleviate the progression of HIV disease.
